Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition
This article was originally published in The Rose Sheet
Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.
You may also be interested in...
Beginning in July 2014 manufacturers must test infant formulas for salmonella and cronobacter before distribution, according to an IFR and guidances FDA released Feb. 6. The rule also requires firms to prove formula meets quality standards including providing all necessary nutrients and appropriate levels of protein.
Under CEO Erik Fyrwald, IFF is committed to improving commercial execution across its four businesses after five years of overall underperformance.
At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.